DNA Methylation and TMPRSS2-ERG Fusion Status in Patients with Prostate Cancer from The Republic of North Macedonia
References
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71– 96
- Lumey LH, Pittman B, Wynder EL. Alcohol use and prostate cancer in U.S. whites: no association in a confirmatory study. Prostate 1998;36(4):250–255.
- de Lamirande, E., O’Flaherty, C. Sperm activation: role of reactive oxygen species and kinases. Biochim Biophys Acta. 2008;1784:106–115.
- Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297– 301
- Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008; 122: 952– 6
- Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008; 72: 1234– 9
- Nygren AO, Ameziane N, Duarte HM, et al. Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005 33(14):e128
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
- Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624–9.
- Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644–8.
- Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S,.et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66: 8337–41.
- Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006;45:717–719.
- M. Folini, P. Gandellini, N. Longoni, Profumo V, Callari M, Pennati M, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer. 2010, 9:12.
- Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Res. 2008;68:3584–3590
- Liu B, Gu X, Huang T, Luan Y, Ding X. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Oncology Reports Jan 2017; 37(1): 201–208.
- Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, et al.Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. Anticancer Research. Sep 2016;36(9): 4787–4793.
- Saramäki O.R, Harjula A.E, Martikainen P.M, Vessella R.L, Tammela T.L.J. Tapio Visakorpi. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clin Cancer Res. Jun 2008;14(11): 3395–3400.
- Krstanoski1 Z, Vokac N.K. , Zagorac A , Pospihalj B , Munda M , Dzeroski S, et al .TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.BMC UROL. 2016 Jul 4;16(1):35. doi: 10.1186/s12894-016-0160-8.
- Yılmaz O, Berber U, Okçelik S, Soydan H, Ateş F and Karademir K. Turk TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens. J Urol. 2016 Jun; 42(2): 60–63. doi: 10.5152/tud.2016.94763
- Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802–1807.
- Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 2007;20:467–473.
- Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826–832.
- Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667–2673.
- Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66:10658–10663.
- Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim R,I et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66:10242–10246.
- Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97: 1690–5.
- FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008;8:230.
- Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69: 1400–6.
- Park JY, Zheng W, Kim D, Jin Q.Cheng, bNagiKumar,a NazeelAhmadb, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev 2007;31:359–65.
- Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560–5.
- Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer DNA Methylation and ERG Expression in Prostate Cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008;68:8954–67.
- Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514–9.
- Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011;129:2454–62.
- Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma, J Urol. 2003 Mar;169(3):1138–42
- Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004 Sep;12(3):631–7.
- Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Volume 205, Issue 2, March 2004, Pages 181–8
- Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J M, Benson MC,, Regina M, et al. DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer DNA Cell Biol. 2012 Feb; 31(2): 187–192.
- Zhou M1, Tokumaru Y, Sidransky D, Epstein JI. Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol. 2004 Jun;171(6 Pt 1):2195–8.
DOI: https://doi.org/10.2478/bjmg-2026-0014 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Language: English
Page range: 63 - 70
Published on: Oct 14, 2026
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 A Trifunovski, A Gavrilovska-Brzanov, S Dohchev, J Janculev, D Trajkovski, I Vujicic, G Severova Andreevska, M Ambardjieva, E Dodikj, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution 4.0 License.